Mina Swiha, Nathan Papa, Zahra Sabahi, Narjess Ayati, Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, Sherrington Li, Shikha Agrawal, Maria Ayers, Adam Hickey, Shikha Sharma, Andrew Nguyen, Louise Emmett
177 Lu-PSMA therapy is an effective treatment in patients with metastatic castration-resistant prostate cancer. SUVmean is a valuable screening biomarker to assess the suitability for 177 Lu-PSMA therapy but requires quantitative software. This study aims to develop a simple, clinically applicable prostate-specific membrane antigen PET/CT score that encompasses the elements of SUVmean without requiring additional quantification. Methods: Datasets from ethics-approved trials of patients with metastatic castration-resistant prostate cancer after androgen receptor signaling inhibition and taxane chemotherapy (or unfit for taxane), who were treated with 177 Lu-PSMA-617 and 177 Lu-PSMA I&T with a pretreatment screening with 68 Ga-PSMA-11 PET/CT, and clinical outcome data, including a prostate-specific antigen (PSA) 50% response rate (PSA50), PSA progression-free survival (PSA-PFS), and overall survival (OS), were included...
April 18, 2024: Journal of Nuclear Medicine